Robert W. Baird initiated coverage on shares of Intellia Therapeutics (NASDAQ:NTLA) in a research report report published on Monday, Benzinga reports. The firm issued an outperform rating and a $23.00 target price on the stock.
A number of other brokerages have also weighed in on NTLA. Evercore ISI started coverage on shares of Homology Medicines in a research report on Thursday, April 11th. They set an outperform rating and a $29.00 target price for the company. BidaskClub upgraded shares of Zynerba Pharmaceuticals from a hold rating to a buy rating in a research report on Thursday, June 20th. Zacks Investment Research lowered shares of GENEL ENERGY PL/ADR from a hold rating to a sell rating in a research report on Thursday, July 4th. Chardan Capital restated a buy rating and set a $57.50 target price on shares of Intellia Therapeutics in a research report on Tuesday, May 28th. Finally, Roth Capital started coverage on shares of Crispr Therapeutics in a research report on Monday, June 10th. They set a buy rating and a $50.00 target price for the company. Eight analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Intellia Therapeutics has a consensus rating of Hold and an average target price of $25.31.
Shares of NASDAQ:NTLA opened at $16.51 on Monday. The company has a debt-to-equity ratio of 0.06, a current ratio of 7.74 and a quick ratio of 7.74. The stock’s fifty day moving average is $14.99. Intellia Therapeutics has a fifty-two week low of $11.03 and a fifty-two week high of $32.95.
Intellia Therapeutics (NASDAQ:NTLA) last issued its earnings results on Thursday, May 2nd. The company reported ($0.49) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.53) by $0.04. Intellia Therapeutics had a negative net margin of 257.28% and a negative return on equity of 31.68%. The firm had revenue of $10.43 million during the quarter, compared to analyst estimates of $9.43 million. During the same quarter in the prior year, the business earned ($0.51) earnings per share. Intellia Therapeutics’s revenue for the quarter was up 39.7% on a year-over-year basis. Research analysts anticipate that Intellia Therapeutics will post -2.4 earnings per share for the current year.
A number of institutional investors have recently added to or reduced their stakes in NTLA. Tortoise Investment Management LLC raised its stake in Intellia Therapeutics by 100.0% during the first quarter. Tortoise Investment Management LLC now owns 2,000 shares of the company’s stock valued at $34,000 after purchasing an additional 1,000 shares in the last quarter. Quantamental Technologies LLC raised its stake in Intellia Therapeutics by 1,170.4% during the first quarter. Quantamental Technologies LLC now owns 3,303 shares of the company’s stock valued at $56,000 after purchasing an additional 3,043 shares in the last quarter. Resources Investment Advisors Inc. purchased a new stake in Intellia Therapeutics during the first quarter valued at $92,000. NumerixS Investment Technologies Inc purchased a new stake in Intellia Therapeutics during the first quarter valued at $110,000. Finally, SG Americas Securities LLC purchased a new stake in Intellia Therapeutics during the fourth quarter valued at $112,000. 74.34% of the stock is currently owned by institutional investors.
Intellia Therapeutics Company Profile
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, and primary hyperoxaluria.
Read More: How To Calculate Debt-to-Equity Ratio
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.